Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in AdultsGlenda Gray, Lubbe Wiesner, Brittany Prigmore et al.|New England Journal of Medicine|2021Cited by 231
Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodiesWilton B. Williams, Barton F. Haynes, Hua-Xin Liao et al.|Science|2015Cited by 202
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trialKenneth H. Mayer, Kelly E. Seaton, Yunda Huang et al.|PLoS Medicine|2017Cited by 132
Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 PreventionLindsey R. Baden, Etienne Karita, Gaudensia Mutua et al.|Annals of Internal Medicine|2016Cited by 84
Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adultsSusan Buchbinder, Nicole Grunenberg, Brittany Sanchez et al.|PLoS ONE|2017Cited by 33